CLINICAL TRIALS PROFILE FOR EXEMESTANE

All Clinical Trials for exemestane

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002777 ↗	Exemestane Compared With Tamoxifen in Treating Women With Locally Recurrent or Metastatic Breast Cancer	Completed	European Organisation for Research and Treatment of Cancer - EORTC	Phase 3	1996-05-01	RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane or tamoxifen may fight cancer by blocking the uptake of estrogen. PURPOSE: Randomized phase II/III trial to compare the effectiveness of exemestane with that of tamoxifen in treating postmenopausal women who have locally recurrent or metastatic breast cancer.
NCT00003418 ↗	Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast Cancer	Unknown status	European Organisation for Research and Treatment of Cancer - EORTC	Phase 3	1998-02-01	RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane or tamoxifen may fight breast cancer by blocking the uptake of estrogen. It is not yet known whether exemestane is more effective than tamoxifen in treating breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of exemestane with that of tamoxifen in treating postmenopausal women with primary breast cancer who have already received 2-3 years of tamoxifen following surgery.
NCT00003418 ↗	Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast Cancer	Unknown status	UNICANCER	Phase 3	1998-02-01	RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane or tamoxifen may fight breast cancer by blocking the uptake of estrogen. It is not yet known whether exemestane is more effective than tamoxifen in treating breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of exemestane with that of tamoxifen in treating postmenopausal women with primary breast cancer who have already received 2-3 years of tamoxifen following surgery.
NCT00003418 ↗	Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast Cancer	Unknown status	International Collaborative Cancer Group	Phase 3	1998-02-01	RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane or tamoxifen may fight breast cancer by blocking the uptake of estrogen. It is not yet known whether exemestane is more effective than tamoxifen in treating breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of exemestane with that of tamoxifen in treating postmenopausal women with primary breast cancer who have already received 2-3 years of tamoxifen following surgery.
NCT00010010 ↗	Exemestane Plus Goserelin in Treating Premenopausal Women With Metastatic Breast Cancer	Completed	National Cancer Institute (NCI)	Phase 2	2000-06-01	RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane plus goserelin may fight breast cancer by reducing the production of estrogen. PURPOSE: Phase II trial to study the effectiveness of exemestane and goserelin in treating premenopausal women who have metastatic breast cancer that has not responded to previous tamoxifen.
NCT00010010 ↗	Exemestane Plus Goserelin in Treating Premenopausal Women With Metastatic Breast Cancer	Completed	New York University School of Medicine	Phase 2	2000-06-01	RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane plus goserelin may fight breast cancer by reducing the production of estrogen. PURPOSE: Phase II trial to study the effectiveness of exemestane and goserelin in treating premenopausal women who have metastatic breast cancer that has not responded to previous tamoxifen.
NCT00010010 ↗	Exemestane Plus Goserelin in Treating Premenopausal Women With Metastatic Breast Cancer	Completed	NYU Langone Health	Phase 2	2000-06-01	RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane plus goserelin may fight breast cancer by reducing the production of estrogen. PURPOSE: Phase II trial to study the effectiveness of exemestane and goserelin in treating premenopausal women who have metastatic breast cancer that has not responded to previous tamoxifen.

Clinical Trial Conditions for exemestane

Condition Name

Condition Name for exemestane
Intervention	Trials
Breast Cancer	109
Breast Neoplasms	31
Metastatic Breast Cancer	30
HER2/Neu Negative	8

Condition MeSH

Condition MeSH for exemestane
Intervention	Trials
Breast Neoplasms	229
Neoplasms	10
Carcinoma	7
Recurrence	6

Clinical Trial Locations for exemestane

Trials by Country

Trials by Country for exemestane
Location	Trials
Italy	124
China	113
Canada	110
Spain	101
Japan	89

Trials by US State

Trials by US State for exemestane
Location	Trials
California	48
Florida	45
Texas	45
New York	41
Washington	37

Clinical Trial Progress for exemestane

Clinical Trial Phase

Clinical Trial Phase for exemestane
Clinical Trial Phase	Trials
Phase 4	9
Phase 3	64
Phase 2/Phase 3	2

Clinical Trial Status

Clinical Trial Status for exemestane
Clinical Trial Phase	Trials
Completed	97
Active, not recruiting	38
Recruiting	37

Clinical Trial Sponsors for exemestane

Sponsor Name

Sponsor Name for exemestane
Sponsor	Trials
Pfizer	41
National Cancer Institute (NCI)	34
Novartis Pharmaceuticals	19

Sponsor Type

Sponsor Type for exemestane
Sponsor	Trials
Other	247
Industry	161
NIH	37